Overview Dividends

(ABBV) AbbVie - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00287Y1091

Biologics, Immunology, Oncology, Neuroscience, Ophthalmology

ABBV EPS (Earnings per Share)

EPS Growth (3Y CAGR): -21.35%
EPS Trend (3Y Correlation): -56.8%

ABBV Revenue

Revenue Growth (3Y CAGR): 1.55%
Revenue Trend (3Y Correlation): 44.4%

Risk via 10d forecast
Volatility	24.0%
Value at Risk 5%th	35.4%

Reward
Sharpe Ratio	0.42
Alpha	3.49

Character
Hurst Exponent	0.266
Beta	0.352

Drawdowns 3y
Max DD	20.74%
Mean DD	7.28%

Description: ABBV AbbVie September 24, 2025

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical firm that develops, manufactures, and commercializes a broad portfolio of medicines across immunology, oncology, neuroscience, eye care, virology, and specialty therapeutics.

Its flagship products include Humira (autoimmune and intestinal diseases), Skyrizi and Rinvoq (psoriasis and inflammatory disorders), Imbruvica and Venclexta (hematologic cancers), Elahere (solid-tumor oncology), and a suite of neuroscience and ophthalmology drugs such as Vraylar, Duopa, Ubrelvy, Qulipta, Ozurdex, and Restasis. The company also markets cosmetic injectables, regenerative-medicine solutions, and gastrointestinal agents like Mavyret, Creon, and Linzess.

In FY 2023 AbbVie generated approximately $58 billion in revenue, with Humira still contributing roughly $2.5 billion despite a 10 % year-over-year decline driven by biosimilar competition. R&D spending was about $5.5 billion, reflecting a continued focus on expanding its oncology pipeline (e.g., Venclexta-based combos) and next-generation immunology candidates. The firm’s operating margin remained above 30 %, a level that is high for the biotech sector.

Key drivers of AbbVie’s outlook include the aging U.S. and global populations that raise demand for chronic-disease biologics, the accelerating rollout of biosimilars that pressure legacy product pricing, and the broader biotech industry’s shift toward gene-editing and cell-therapy platforms, which could reshape competitive dynamics over the next 5-10 years.

For a deeper, data-rich assessment of how these trends may affect AbbVie’s valuation, you may find it worthwhile to explore the analysis on ValueRay.

ABBV Stock Overview

Market Cap in USD	387,340m
Sub-Industry	Biotechnology
IPO / Inception	2013-01-02
Return 12m vs S&P 500	+14.65%
Analyst Rating	4.0 of 5

ABBV Dividends

Dividend Yield	2.99%
Yield on Cost 5y	8.38%
Yield CAGR 5y	7.06%
Payout Consistency	100.0%
Payout Ratio	69.4%

ABBV Growth Ratios

CAGR	17.84%
CAGR/Max DD Calmar Ratio	0.86
CAGR/Mean DD Pain Ratio	2.45
Current Volume	4567k
Average Volume	5411.9k

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (2.39b TTM) > 0 and > 6% of Revenue (6% = 3.58b TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA 4.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -18.19% (prev -27.51%; Δ 9.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.16 (>3.0%) and CFO 20.86b > Net Income 2.39b (YES >=105%, WARN >=100%)

Net Debt (63.11b) to EBITDA (10.66b) ratio: 5.92 <= 3.0 (WARN <= 3.5)

Current Ratio 0.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.77b) change vs 12m ago 0.0% (target <= -2.0% for YES)

Gross Margin 76.21% (prev 67.21%; Δ 9.00pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 43.01% (prev 38.72%; Δ 4.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.10 (EBITDA TTM 10.66b / Interest Expense TTM 2.81b) >= 6 (WARN >= 3)

Altman Z'' -0.85

(A) -0.08 = (Total Current Assets 28.54b - Total Current Liabilities 39.39b) / Total Assets 133.90b

(B) -0.11 = Retained Earnings (Balance) -14.23b / Total Assets 133.90b

(D) -0.12 = Book Value of Equity -15.79b / Total Liabilities 136.50b

Total Rating: -0.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 49.80

1. Piotroski 4.0pt = -1.0

2. FCF Yield 4.57% = 2.28

3. FCF Margin 34.49% = 7.50

4. Debt/Equity -26.02 = -2.50

5. Debt/Ebitda 5.92 = -2.50

6. ROIC - WACC (= -5.58)% = -6.98

7. RoE 498.8% = 2.50

8. Rev. Trend 44.44% = 3.33

9. EPS Trend -56.82% = -2.84

What is the price of ABBV shares?

As of November 10, 2025, the stock is trading at USD 219.16 with a total of 4,566,957 shares traded.
Over the past week, the price has changed by +3.40%, over one month by -4.31%, over three months by +11.13% and over the past year by +30.04%.

Is AbbVie a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, AbbVie (NYSE:ABBV) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 49.80 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABBV is around 242.04 USD . This means that ABBV is currently undervalued and has a potential upside of +10.44% (Margin of Safety).

Is ABBV a buy, sell or hold?

AbbVie has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ABBV.

Strong Buy: 12
Buy: 4
Hold: 12
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ABBV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	241.3	10.1%
Analysts Target Price	241.3	10.1%
ValueRay Target Price	265.6	21.2%

ABBV Fundamental Data Overview November 09, 2025

Market Cap USD = 387.34b (387.34b USD * 1.0 USD.USD)
P/E Trailing = 167.2977
P/E Forward = 16.835
P/S = 6.4942
P/B = 50.4573
P/EG = 0.4252
Beta = 0.352
Revenue TTM = 59.64b USD
EBIT TTM = 3.09b USD
EBITDA TTM = 10.66b USD
Long Term Debt = 60.34b USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.77b USD (from shortTermDebt, last quarter)
Debt = 68.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.11b USD (from netDebt column, last quarter)
Enterprise Value = 450.41b USD (387.34b + Debt 68.74b - CCE 5.67b)
Interest Coverage Ratio = 1.10 (Ebit TTM 3.09b / Interest Expense TTM 2.81b)
FCF Yield = 4.57% (FCF TTM 20.57b / Enterprise Value 450.41b)
FCF Margin = 34.49% (FCF TTM 20.57b / Revenue TTM 59.64b)
Net Margin = 4.01% (Net Income TTM 2.39b / Revenue TTM 59.64b)
Gross Margin = 76.21% ((Revenue TTM 59.64b - Cost of Revenue TTM 14.19b) / Revenue TTM)
Gross Margin QoQ = 78.51% (prev 84.42%)
Tobins Q-Ratio = 3.36 (Enterprise Value 450.41b / Total Assets 133.90b)
Interest Expense / Debt = 0.97% (Interest Expense 667.0m / Debt 68.74b)
Taxrate = 73.67% (526.0m / 714.0m)
NOPAT = 813.1m (EBIT 3.09b * (1 - 73.67%))
Current Ratio = 0.72 (Total Current Assets 28.54b / Total Current Liabilities 39.39b)
Debt / Equity = -26.02 (negative equity) (Debt 68.74b / totalStockholderEquity, last quarter -2.64b)
Debt / EBITDA = 5.92 (Net Debt 63.11b / EBITDA 10.66b)
Debt / FCF = 3.07 (Net Debt 63.11b / FCF TTM 20.57b)
Total Stockholder Equity = 480.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.79% (Net Income 2.39b / Total Assets 133.90b)
RoE = 498.8% (Net Income TTM 2.39b / Total Stockholder Equity 480.0m)
RoCE = 5.08% (EBIT 3.09b / Capital Employed (Equity 480.0m + L.T.Debt 60.34b))
RoIC = 1.15% (NOPAT 813.1m / Invested Capital 70.69b)
WACC = 6.73% (E(387.34b)/V(456.08b) * Re(7.88%) + D(68.74b)/V(456.08b) * Rd(0.97%) * (1-Tc(0.74)))
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.09% ; FCFE base≈18.59b ; Y1≈18.34b ; Y5≈18.95b
Fair Price DCF = 190.1 (DCF Value 336.02b / Shares Outstanding 1.77b; 5y FCF grow -2.17% → 3.0% )
EPS Correlation: -56.82 | EPS CAGR: -21.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: 44.44 | Revenue CAGR: 1.55% | SUE: 0.41 | # QB: 0

Additional Sources for ABBV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle